4//SEC Filing
Shafer Christina 4
Accession 0001104659-25-011240
CIK 0001267813other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 9:12 AM ET
Size
20.9 KB
Accession
0001104659-25-011240
Insider Transaction Report
Form 4
Shafer Christina
CHIEF COMMERCIAL OFFICER
Transactions
- Disposition to Issuer
Common Stock
2025-02-07$0.55/sh−18,778$10,328→ 48,628 total - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-11−57,900→ 0 totalExercise: $10.40Exp: 2032-02-04→ Common Stock (57,900 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-11−15,000→ 0 totalExercise: $12.60Exp: 2031-01-15→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-11−128,000→ 0 totalExercise: $13.71Exp: 2030-11-09→ Common Stock (128,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-11−49,125→ 0 totalExercise: $1.40Exp: 2034-06-18→ Common Stock (49,125 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-11−78,188→ 0 totalExercise: $5.94Exp: 2033-01-26→ Common Stock (78,188 underlying) - Disposition to Issuer
Common Stock
2025-02-11$0.55/sh−48,628$26,745→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-11−98,250→ 0 totalExercise: $9.74Exp: 2034-01-18→ Common Stock (98,250 underlying)
Footnotes (3)
- [F1]On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
- [F2]Represents 48,628 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
- [F3]Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Documents
Issuer
MARINUS PHARMACEUTICALS, INC.
CIK 0001267813
Entity typeother
Related Parties
1- filerCIK 0001934412
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 9:12 AM ET
- Size
- 20.9 KB